Castle Biosciences (CSTL) to Release Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) will post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Castle Biosciences to post earnings of ($0.37) per share for the quarter. Castle Biosciences has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. The firm had revenue of $66.12 million for the quarter, compared to analysts’ expectations of $51.32 million. On average, analysts expect Castle Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL opened at $21.53 on Tuesday. Castle Biosciences has a 12 month low of $9.26 and a 12 month high of $26.70. The stock has a market cap of $591.00 million, a price-to-earnings ratio of -9.97 and a beta of 0.93. The stock’s 50 day moving average price is $21.01 and its 200 day moving average price is $20.16.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,947 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $20.35, for a total value of $39,621.45. Following the transaction, the insider now owns 65,418 shares of the company’s stock, valued at $1,331,256.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Castle Biosciences news, Director Daniel Bradbury sold 2,074 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $23.20, for a total transaction of $48,116.80. Following the sale, the director now directly owns 33,870 shares of the company’s stock, valued at approximately $785,784. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Derek J. Maetzold sold 1,947 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $20.35, for a total transaction of $39,621.45. Following the sale, the insider now directly owns 65,418 shares in the company, valued at $1,331,256.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,483 shares of company stock valued at $1,059,531. Corporate insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. KeyCorp boosted their target price on Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, March 1st. Scotiabank upped their price target on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a report on Friday, March 1st.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.